{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:59:31Z","timestamp":1790812771442,"version":"4.1.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","onlinejacc.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jacc.2018.01.016","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T14:07:15Z","timestamp":1520258835000},"page":"1130-1148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Spectrum of Restrictive and Infiltrative\u00a0Cardiomyopathies"],"prefix":"10.1016","volume":"71","author":[{"given":"Naveen L.","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. William","family":"Dec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2018.01.016_bib1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","article-title":"Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies","volume":"93","author":"Richardson","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification\u00a0of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.01.016_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1056\/NEJM199701233360407","article-title":"Restrictive cardiomyopathy","volume":"336","author":"Kushwaha","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.016_bib4","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/0002-8703(91)90587-8","article-title":"Constrictive pericarditis versus restrictive cardiomyopathy: a reappraisal and update of diagnostic criteria","volume":"122","author":"Vaitkus","year":"1991","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2018.01.016_bib5","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2016.01.076","article-title":"Constrictive pericarditis versus restrictive cardiomyopathy?","volume":"67","author":"Garcia","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.crad.2011.05.020","article-title":"Cardiac MRI in restrictive cardiomyopathy","volume":"67","author":"Gupta","year":"2012","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib7","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehs397","article-title":"Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.01.016_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1532-429X-13-15","article-title":"The relative atrial volume ratio and late gadolinium enhancement provide additive information to differentiate constrictive pericarditis from restrictive cardiomyopathy","volume":"13","author":"Cheng","year":"2011","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jacc.2018.01.016_bib9","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jacc.2008.06.049","article-title":"Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping","volume":"52","author":"Iles","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/RTI.0000000000000199","article-title":"Magnetic resonance imaging applications on infiltrative cardiomyopathies","volume":"31","author":"Muehlberg","year":"2016","journal-title":"J\u00a0Thorac Imaging"},{"key":"10.1016\/j.jacc.2018.01.016_bib11","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcmg.2015.10.027","article-title":"LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis","volume":"9","author":"Boynton","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2018.01.016_bib12","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2016.08.050","article-title":"Differentiation of constriction and restriction: complex cardiovascular hemodynamics","volume":"68","author":"Geske","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib13","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.107.186093","article-title":"The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology","volume":"116","author":"Cooper","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCHEARTFAILURE.112.000087","article-title":"Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009","volume":"6","author":"Bennett","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2018.01.016_bib15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0002-9149(00)01278-9","article-title":"Comparison of new Doppler echocardiographic methods to differentiate constrictive pericardial heart disease and restrictive cardiomyopathy","volume":"87","author":"Rajagopalan","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0735-1097(97)82756-8","article-title":"Pericardial thickness measured with transesophageal echocardiography: feasibility and potential clinical usefulness","volume":"29","author":"Ling","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib17","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.CIR.93.11.2007","article-title":"Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis","volume":"93","author":"Hurrell","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.79.2.357","article-title":"Differentiation of constrictive pericarditis and restrictive cardiomyopathy by Doppler echocardiography","volume":"79","author":"Hatle","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0735-1097(94)90514-2","article-title":"Diagnostic role of Doppler echocardiography in constrictive pericarditis","volume":"23","author":"Oh","year":"1994","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/CIRCIMAGING.113.001613","article-title":"Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria","volume":"7","author":"Welch","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2018.01.016_bib21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ejechocard\/jen258","article-title":"Using mitral 'annulus reversus' to diagnose constrictive pericarditis","volume":"10","author":"Reuss","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacc.2018.01.016_bib22","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/hc3401.095705","article-title":"Annulus paradoxus: transmitral flow velocity to mitral annular velocity ratio is inversely proportional to pulmonary capillary wedge pressure in patients with constrictive pericarditis","volume":"104","author":"Ha","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0735-1097(95)00434-3","article-title":"Differentiation of constrictive pericarditis from restrictive cardiomyopathy: assessment of left ventricular diastolic velocities in longitudinal axis by Doppler tissue imaging","volume":"27","author":"Garcia","year":"1996","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcmg.2007.10.006","article-title":"Disparate patterns of left ventricular mechanics differentiate constrictive pericarditis from restrictive cardiomyopathy","volume":"1","author":"Sengupta","year":"2008","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2018.01.016_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1148\/radiology.182.2.1732952","article-title":"Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging","volume":"182","author":"Masui","year":"1992","journal-title":"Radiology"},{"key":"10.1016\/j.jacc.2018.01.016_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199907293410515","article-title":"Diagnosis of constrictive pericarditis by tagged cine magnetic resonance imaging","volume":"341","author":"Kojima","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.016_bib27","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1161\/CIRCULATIONAHA.110.955229","article-title":"Lack of slippage by cardiovascular magnetic resonance imaging is sine qua non for constrictive pericarditis","volume":"123","author":"Bogabathina","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib28","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.jacc.2007.02.061","article-title":"Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype","volume":"49","author":"Kubo","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/HCO.0b013e32832a1d2e","article-title":"Restrictive cardiomyopathy","volume":"24","author":"Mogensen","year":"2009","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI200316336","article-title":"Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations","volume":"111","author":"Mogensen","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2018.01.016_bib31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijcard.2007.07.108","article-title":"Deletion in TNNI3 gene is associated with restrictive cardiomyopathy","volume":"131","author":"Kostareva","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib32","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/hrt.2007.134684","article-title":"Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes","volume":"94","author":"Kaski","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2018.01.016_bib33","first-page":"1","article-title":"Novel phenotype-genotype correlations of restrictive cardiomyopathy with myosin-binding protein C (MYBPC3) gene mutations tested by next-generation sequencing","volume":"4","author":"Wu","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2018.01.016_bib34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1399-0004.2008.01062.x","article-title":"Cardiac troponin T mutation in familial cardiomyopathy with variable remodeling and restrictive physiology","volume":"74","author":"Menon","year":"2008","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2018.01.016_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.hfc.2009.11.005","article-title":"Genetics of restrictive cardiomyopathy","volume":"6","author":"Sen-Chowdhry","year":"2010","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.jacc.2018.01.016_bib36","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/hmg\/dds022","article-title":"Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations","volume":"21","author":"Purevjav","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jacc.2018.01.016_bib37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/humu.22942","article-title":"Mutations in FLNC are associated with familial restrictive cardiomyopathy","volume":"37","author":"Brodehl","year":"2016","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacc.2018.01.016_bib38","doi-asserted-by":"crossref","first-page":"H2604","DOI":"10.1152\/ajpheart.91506.2007","article-title":"Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopathy mutation, R193H, in cardiac TnI","volume":"294","author":"Du","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib39","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/j.jacc.2014.09.071","article-title":"Disturbance in Z-disk mechanosensitive proteins induced by a persistent mutant myopalladin causes familial restrictive cardiomyopathy","volume":"64","author":"Huby","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ceb.2015.01.004","article-title":"Desmin related disease: a matter of cell survival failure","volume":"32","author":"Capetanaki","year":"2015","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jacc.2018.01.016_bib41","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1034\/j.1399-0004.2001.590406.x","article-title":"Clinical and molecular studies of a large family with desmin-associated restrictive cardiomyopathy","volume":"59","author":"Zhang","year":"2001","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2018.01.016_bib42","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/humu.23248","article-title":"The novel alphaB-crystallin (CRYAB) mutation p.D109G causes restrictive cardiomyopathy","volume":"38","author":"Brodehl","year":"2017","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacc.2018.01.016_bib43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejheart.2005.11.003","article-title":"Desmin accumulation restrictive cardiomyopathy and atrioventricular block associated with desmin gene defects","volume":"8","author":"Arbustini","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2018.01.016_bib44","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/j.jacc.2016.08.079","article-title":"Clinical and mechanistic insights Into the genetics of cardiomyopathy","volume":"68","author":"Burke","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jacc.2014.05.027","article-title":"The MOGE(S) classification of cardiomyopathy for clinicians","volume":"64","author":"Arbustini","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib46","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.bbrc.2005.10.116","article-title":"Drastic Ca2+ sensitization of myofilament associated with a small structural change in troponin I in inherited restrictive cardiomyopathy","volume":"338","author":"Yumoto","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacc.2018.01.016_bib47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0167-5273(98)00013-8","article-title":"Collagen subtypes and matrix metalloproteinase in idiopathic restrictive cardiomyopathy","volume":"64","author":"Hayashi","year":"1998","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib48","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0002-9149(97)00601-2","article-title":"Morphologic spectrum of primary restrictive cardiomyopathy","volume":"80","author":"Angelini","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib49","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.jacc.2005.03.050","article-title":"The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy","volume":"45","author":"Leya","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib50","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.cardfail.2007.05.001","article-title":"Utility of BNP in differentiating constrictive pericarditis from restrictive cardiomyopathy in patients with renal insufficiency","volume":"13","author":"Reddy","year":"2007","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2018.01.016_bib51","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/01.CIR.101.21.2490","article-title":"Clinical profile and outcome of idiopathic restrictive cardiomyopathy","volume":"101","author":"Ammash","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-6143.2007.02027.x","article-title":"Twenty-year experience with heart transplantation for infants and children with restrictive cardiomyopathy: 1986-2006","volume":"8","author":"Bograd","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jacc.2018.01.016_bib53","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCHEARTFAILURE.110.959288","article-title":"Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy","volume":"4","author":"Topilsky","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2018.01.016_bib54","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2009.12.040","article-title":"Infiltrative cardiovascular diseases: cardiomyopathies that look alike","volume":"55","author":"Seward","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib55","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/CIRCULATIONAHA.114.009789","article-title":"Anderson-Fabry disease and other lysosomal storage disorders","volume":"130","author":"Nagueh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib56","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/eurheartj\/ehp588","article-title":"Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity","volume":"31","author":"Wu","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.01.016_bib57","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.01.016_bib58","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","article-title":"Early detection of Fabry cardiomyopathy by tissue Doppler imaging","volume":"107","author":"Pieroni","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib59","doi-asserted-by":"crossref","first-page":"e001661","DOI":"10.1161\/CIRCGENETICS.116.001661","article-title":"Previously unreported in women galactosidase alpha pro409Ser variant is associated with Fabry disease","volume":"10","author":"Luis","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2018.01.016_bib60","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib61","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.01.016_bib62","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jacc.2018.01.016_bib63","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.2009.371","article-title":"Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy","volume":"301","author":"Maron","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.01.016_bib64","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mus.20471","article-title":"Novel Lamp-2 gene mutation and successful treatment with heart transplantation in a large family with Danon disease","volume":"33","author":"Echaniz-Laguna","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacc.2018.01.016_bib65","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib66","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacc.2018.01.016_bib67","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2018.01.016_bib68","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib69","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2018.01.016_bib70","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"(light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib71","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/hrt.74.5.541","article-title":"Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation","volume":"74","author":"Dubrey","year":"1995","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2018.01.016_bib72","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib73","doi-asserted-by":"crossref","first-page":"P32","DOI":"10.1186\/1750-1172-10-S1-P32","article-title":"Prevalence, risk factors and correlation with cardiac involvement of carpal tunnel syndrome in amyloidosis","volume":"10","author":"Milandri","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jacc.2018.01.016_bib74","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.jacc.2018.01.016_bib75","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ajh.21934","article-title":"Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Gertz","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jacc.2018.01.016_bib76","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","article-title":"Cardiac amyloidosis: pathology, nomenclature, and typing","volume":"24","author":"Maleszewski","year":"2015","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.jacc.2018.01.016_bib77","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.echo.2007.02.025","article-title":"Detection of left ventricular systolic dysfunction in cardiac amyloidosis with\u00a0strain rate echocardiography","volume":"20","author":"Bellavia","year":"2007","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2018.01.016_bib78","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib79","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jcmg.2013.01.007","article-title":"T1 mapping in cardiac amyloidosis: can we get there from here?","volume":"6","author":"Ruberg","year":"2013","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2018.01.016_bib80","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2004.10.028","article-title":"Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement","volume":"95","author":"Murtagh","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib81","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib82","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.echo.2013.12.010","article-title":"Advanced cardiac amyloidosis associated with normal interventricular septal thickness: an uncommon presentation of infiltrative cardiomyopathy","volume":"27","author":"Suresh","year":"2014","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2018.01.016_bib83","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.carpath.2012.09.001","article-title":"Relationship between monoclonal gammopathy and cardiac amyloid type","volume":"22","author":"Maleszewski","year":"2013","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.jacc.2018.01.016_bib84","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2018.01.016_bib85","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2018.01.016_bib86","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.01.016_bib87","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human Phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2018.01.016_bib88","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.016_bib89","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.jacc.2016.03.593","article-title":"Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure","volume":"67","author":"Sperry","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib90","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ajt.13025","article-title":"Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era","volume":"15","author":"Davis","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jacc.2018.01.016_bib91","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","article-title":"Autologous stem cell transplantation for primary systemic amyloidosis","volume":"99","author":"Comenzo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2018.01.016_bib92","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib93","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/13506120410001673884","article-title":"End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors","volume":"11","author":"Lobato","year":"2004","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2018.01.016_bib94","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s004390050199","article-title":"Revised transthyretin Ile 122 allele frequency in African-Americans","volume":"98","author":"Jacobson","year":"1996","journal-title":"Hum Genet"},{"key":"10.1016\/j.jacc.2018.01.016_bib95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.016_bib96","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2018.01.016_bib97","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/CIRCULATIONAHA.115.020351","article-title":"Wild-type transthyretin amyloid cardiomyopathy: A missed cause of heart failure with preserved ejection fraction with evolving treatment implications","volume":"133","author":"Liu","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib98","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.01.016_bib99","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.01.016_bib100","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2018.01.016_bib101","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib102","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jmri.24078","article-title":"Markedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T mapping","volume":"38","author":"Brooks","year":"2013","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.jacc.2018.01.016_bib103","doi-asserted-by":"crossref","first-page":"1166.e1","DOI":"10.1016\/j.cjca.2016.05.008","article-title":"Wild-type transthyretin cardiac amyloidosis: Novel insights from advanced imaging","volume":"32","author":"Narotsky","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib104","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","article-title":"Natural history and therapy of AL cardiac amyloidosis","volume":"20","author":"Grogan","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2018.01.016_bib105","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib106","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","article-title":"Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy","volume":"7","author":"Longhi","year":"2014","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2018.01.016_bib107","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2018.01.016_bib108","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.016_bib109","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/postgradmedj-2014-133224","article-title":"The transthyretin amyloidoses: advances in therapy","volume":"91","author":"Dubrey","year":"2015","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jacc.2018.01.016_bib110","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.hrthm.2012.02.033","article-title":"Prophylactic pacemaker implantation in familial amyloid polyneuropathy","volume":"9","author":"Algalarrondo","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2018.01.016_bib111","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.jacc.2018.01.016_bib112","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/lt.21996","article-title":"Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience","volume":"16","author":"Barreiros","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jacc.2018.01.016_bib113","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ctr.12053","article-title":"Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy","volume":"27","author":"Nelson","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jacc.2018.01.016_bib114","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/CND.0000000000000110","article-title":"Rapidly progressive transthyretin-mediated amyloidosis in a Domino liver transplant recipient of a Ser23Asn donor","volume":"17","author":"Dixit","year":"2016","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.jacc.2018.01.016_bib115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00007890-199707150-00014","article-title":"Progression of ventricular wall thickening after liver transplantation for familial amyloidosis","volume":"64","author":"Dubrey","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.jacc.2018.01.016_bib116","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.bbrc.2008.12.095","article-title":"Proportion between wild-type and mutant protein in truncated compared to full-length ATTR: an analysis on transplanted transthyretin T60A amyloidosis patients","volume":"379","author":"Ihse","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacc.2018.01.016_bib117","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/13506129.2013.853660","article-title":"Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis","volume":"21","author":"Thenappan","year":"2014","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2018.01.016_bib118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Castano","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2018.01.016_bib119","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.01.016_bib120","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2018.01.016_bib121","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2018.01.016_bib122","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.016_bib123","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/13506129.2012.673140","article-title":"Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy","volume":"19 Suppl 1","author":"Ackermann","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2018.01.016_bib124","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.jacc.2018.01.016_bib125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19 Suppl 1","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2018.01.016_bib126","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/14779072.2015.1093936","article-title":"Novel strategies for the diagnosis and treatment of cardiac amyloidosis","volume":"13","author":"Palladini","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jacc.2018.01.016_bib127","doi-asserted-by":"crossref","first-page":"25096","DOI":"10.1074\/jbc.M116.738138","article-title":"Novel antibody for the treatment of transthyretin amyloidosis","volume":"291","author":"Hosoi","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2018.01.016_bib128","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718301219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718301219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:10:21Z","timestamp":1693555821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109718301219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":128,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0735109718301219"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2018.01.016","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spectrum of Restrictive and Infiltrative\u00a0Cardiomyopathies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.01.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}